Literature DB >> 7729471

Fluoroquinolone resistance in staphylococci: new challenges.

C C Sanders1, W E Sanders, K S Thomson.   

Abstract

Staphylococci show only marginal susceptibility to the newer fluoroquinolones. Minimum inhibitory concentrations (MICs) for susceptible strains usually range from 0.25 to 2.0 mg/l. As a single mutational event involving the gyrase target or permeability diminishes fluoroquinolone susceptibility fourfold on average, such a mutation in staphylococci would lead to a clinical level of resistance. Therefore, it is not surprising that in some institutions, the use of fluoroquinolones has been quickly followed by greatly increased prevalence of fluoroquinolone-resistant staphylococci. The greatest increase in resistance has been seen among methicillin-resistant staphylococci although increased prevalence of resistance among Staphylococcus saprophyticus and other methicillin-susceptible staphylococci has also been reported. Clinical isolates of staphylococci recovered since the introduction of the fluoroquinolones fall into three fluoroquinolone susceptibility groups: susceptible (MIC < 0.5 mg/l), moderately resistant (MIC 0.5 to 4 mg/l) and highly resistant (MIC > 4 mg/l). The first group represents wild type strains while the second and third groups represent single- and multiple-step mutants, respectively. To prevent increasing prevalence of isolates in the second and third groups, it would be prudent to avoid use of quinolones whenever possible. However, when it is necessary, a fluoroquinolone, which achieves serum/tissue levels eight times the MIC of the infecting strain, should be used.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729471

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Immunization with alpha-toxin toxoid protects the cornea against tissue damage during experimental Staphylococcus aureus keratitis.

Authors:  E B Hume; J J Dajcs; J M Moreau; R J O'Callaghan
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.

Authors:  J M Entenza; J Vouillamoz; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 3.  Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

4.  MRSA and cataract surgery - reflections for practice.

Authors:  L F Porter; R U Khan; A Hannan; S P Kelly
Journal:  Clin Ophthalmol       Date:  2010-10-21

5.  Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.

Authors:  J M Entenza; O Marchetti; M P Glauser; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

6.  Efficacy of trovafloxacin, a new quinolone antibiotic, in experimental staphylococcal endocarditis due to oxacillin-resistant strains.

Authors:  A S Bayer; C Li; M Ing
Journal:  Antimicrob Agents Chemother       Date:  1998-07       Impact factor: 5.191

7.  Impact of the high-affinity proline permease gene (putP) on the virulence of Staphylococcus aureus in experimental endocarditis.

Authors:  A S Bayer; S N Coulter; C K Stover; W R Schwan
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

8.  Screening of crude extracts of six medicinal plants used in South-West Nigerian unorthodox medicine for anti-methicillin resistant Staphylococcus aureus activity.

Authors:  Kabir O Akinyemi; Olukayode Oladapo; Chidi E Okwara; Christopher C Ibe; Kehinde A Fasure
Journal:  BMC Complement Altern Med       Date:  2005-03-11       Impact factor: 3.659

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.